references
RESEARCH
LEAD OPTIMIZATION
Overall objective: Establish a robust portfolio of optimized leads/pre-clinical candidates for the three kinetoplastid diseases. Main partners: AbbVie, USA; Anacor Pharmaceuticals Inc.,
DNDI-5421 DNDI-5610
LEISHMANIASIS
Chagas Lead Optimization
CHAGAS DISEASE
USA; AstraZeneca, UK; Brazilian Biosciences National Laboratory, Brazil; Celgene, USA; Centre for Drug Candidate Optimization, Monash University, Australia; Epichem, Australia; Eskitis Institute for Cell and Molecular Therapies, Griffith University, Australia; Fundaçao de Apoio Universidade Federale de Sao Paolo, USP São Carlos, Brazil; GlaxoSmithKline, Tres Cantos, Spain; iThemba LABS, South Africa; Laboratory of Microbiology, Parasitology and Hygiene, Antwerp University, Belgium; London School of Hygiene and Tropical Medicine, UK; Merck, USA; Novartis Institute for Tropical Diseases, Singapore; Pfizer Ltd, UK; Sanofi, France; SCYNEXIS Inc., USA; TB Alliance, USA; TCG Life Sciences, India; Sandexis, UK; Universidade Estadual de Campinas, Brazil; University of Auckland, New Zealand; WuXi AppTec, China
Objective: Maintain back-up oxaboroles which could replace the pre-clinical candidate DNDI-6148 in case it does not succeed in development. Main partners: Anacor Pharmaceuticals Inc., USA; Laboratory
of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; WuXi AppTech, China; Sandexis, UK
Aminopyrazoles
LEISHMANIASIS
Objective: Select a pre-clinical candidate from the aminopyrazole series for the treatment of VL. Main partners: Takeda Pharmaceutical Company Ltd, Japan;
Monash University, Australia; Epichem, Australia; Fundaçao de Apoio Universidade Federale de Sao Paolo (FapUnifesp), Brazil; Griffith University, Australia; London School of Hygiene and Tropical Medicine, UK; WuXi AppTech, China; LNBio/CNPEM, Brazil; University of Campinas, Brazil; AbbVie, USA; Sanofi, France; Sandexis, UK; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; TCG Life Sciences, India
Objective: Optimize leads issued from Hit-to-Lead series and identify pre-clinical candidates with the potential to fulfill the target product profile (TPP). Main partners: Centre for Drug Candidate Optimization,
SCYX-1330682 SCYX-1608210
WuXi AppTech, China; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; Pfizer, UK; Sandexis, UK
HAT
Biomarkers
CHAGAS DISEASE
Objective: Maintain back-up oxaboroles which could replace the drug candidate SCYX-7158 in case it does not succeed in development. Main partners: Anacor Pharmaceuticals Inc., USA; Pace
CGH VL series 1
LEISHMANIASIS
Objective: Identify and evaluate new biological markers of therapeutic efficacy in chronic Chagas disease. Main partners: Texas Biomedical Research, USA; University
University, USA; The Laboratory of Microbioloy, Parasitology, and Hygiene, University of Antwerp, Belgium; SCYNEXIS Inc., USA
LEISHMANIASIS
Objective: Select a pre-clinical candidate from the CGH VL series 1 for the treatment of VL. Main partners: Celgene Global Health, USA; Laboratory of
Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; WuXi AppTech, China; Sandexis, UK
Leish H2L
Chagas H2L
CHAGAS DISEASE
Universidade Federale de Sao Paolo, Brazil; Centre for Drug Candidate Optimization, Monash University, Australia; TCG Lifesciences, India; Sandexis, UK; WuXi AppTech, China; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; Griffith University, Australia; GlaxoSmithKline, Tres Cantos, Spain; Sanofi, France; Anacor Pharmaceuticals Inc., USA; Merck, USA; AstraZeneca, UK; AbbVie, USA
